Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Diseases × zipalertinib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lung Diseases 1 Carcinoma 1

Interventions

Carboplatin 7 Pemetrexed 3 Paclitaxel 3 durvalumab 2 atezolizumab 2 Nivolumab 2 Ipilimumab 2 Cisplatin 2 Bevacizumab 2 zipalertinib 1 toripalimab 1 sotorasib 1 sitravatinib 1 sintilimab 1 pembrolizumab 1 demcizumab 1 ceralasertib 1 cemiplimab 1 apatinib 1 aflibercept 1 Toll-Like Receptor 1 1 Radiotherapy 1 Omacor 1 Etoposide 1 Erlotinib Hydrochloride 1 Diarylheptanoids 1 Diagnostic Imaging 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05967689 2026-03-10

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡